Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Sands · SciRah

Researcher profile · Semantic Scholar

J. Sands

Share profile

J. Sands — researcher profile on SciRah

h-index: 24
Works: 80
Citations: 2,459

Most-cited papers

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
A. Ganti, B. Loo, M. Bassetti, C. Blakely +30 more
2021The Journal of the National Comprehensive Cancer Network423 citations Open access
Semantic Scholar
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
J. Trigo, V. Subbiah, B. Besse, V. Moreno +29 more
2020The Lancet Oncology401 citations
Semantic Scholar
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
I. Cañadas, Rohit Thummalapalli, J. W. Kim, S. Kitajima +34 more
2018Nature Medicine275 citations Open access
Semantic Scholar
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.
G. Kalemkerian, Billy W. Loo, W. Akerley, A. Attia +28 more
2018The Journal of the National Comprehensive Cancer Network268 citations
Semantic Scholar
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022.
D. Wood, E. Kazerooni, D. Aberle, A. Berman +34 more
2022The Journal of the National Comprehensive Cancer Network121 citations Open access
Semantic Scholar
Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.
J. Sands, M. Tammemagi, S. Couraud, D. Baldwin +9 more
2020Journal of Thoracic Oncology109 citations Open access
Semantic Scholar
PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
Erik H. Knelson, Shetal A. Patel, J. Sands
2021Cancers64 citations Open access
Semantic Scholar
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
K. Kehl, D. Zahrieh, Ping Yang, S. Hillman +13 more
2022JAMA Oncology52 citations Open access
Semantic Scholar
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
J. Sands, Tom Nguyen, Priyanka Shivdasani, A. Sacher +6 more
2019Lung Cancer42 citations
Semantic Scholar
OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
A. Spira, A. Lisberg, J. Sands, J. Greenberg +13 more
202139 citations Open access
Semantic Scholar
Combined chemoradiation as primary treatment for invasive male urethral cancer.
M. Kent, L. Zinman, L. Girshovich, J. Sands +1 more
2015Journal of Urology38 citations
Semantic Scholar
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
V. Subbiah, L. Paz-Ares, B. Besse, V. Moreno +30 more
2020Lung Cancer37 citations Open access
Semantic Scholar
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
J. Rotow, D. Costa, C. Paweletz, M. Awad +14 more
202034 citations
Semantic Scholar
Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
J. Sands, Qian-Yi Li, J. Hornberger
2017Lung Cancer32 citations
Semantic Scholar
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.
Yi Lee, E. Clark, Marina S. D. Milan, C. Champagne +11 more
2020JCO Precision Oncology31 citations Open access
Semantic Scholar
Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders.
J. Sands, J. Tuscano
2010Autoimmunity Reviews31 citations
Semantic Scholar
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
R. Huang, D. Carbone, Gerald Li, A. Schrock +8 more
2023Journal for ImmunoTherapy of Cancer30 citations Open access
Semantic Scholar
LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
E. Garon, M. Johnson, A. Lisberg, A. Spira +12 more
2021Annals of Oncology29 citations Open access
Semantic Scholar
MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
E. Garon, M. Johnson, A. Lisberg, A. Spira +11 more
2021Journal of Thoracic Oncology27 citations Open access
Semantic Scholar
An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
Shetal A. Patel, W. Petty, J. Sands
2021Therapeutic Advances in Medical Oncology27 citations Open access
Semantic Scholar
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)
J. Sands, S. Mandrekar, D. Kozono, G. Oxnard +14 more
2021Immunotherapy26 citations Open access
Semantic Scholar
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
B. Ricciuti, A. Naqash, J. Naidoo, Kartik Sehgal +19 more
2020JTO Clinical and Research Reports26 citations Open access
Semantic Scholar
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
J. Sands, S. Mandrekar, G. Oxnard, D. Kozono +14 more
2020Journal of Clinical Oncology25 citations
Semantic Scholar
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).
B. Besse, L. Paz-Ares, Solange Peters, F. Cappuzzo +8 more
2023Journal of Clinical Oncology24 citations
Semantic Scholar
Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy
T. Semrad, Edward J. Kim, Michael S. Tanaka, J. Sands +6 more
2017Cancer Treatment and Research Communications24 citations Open access
Semantic Scholar
A dose-finding study followed by a phase II randomized, placebo-controlled trial of chemoradiotherapy with or without veliparib in stage III non-small cell lung cancer: SWOG 1206 (8811)
A. Argiris, Jie-Ling Miao, M. Cristea, Allen M. Chen +14 more
2021Clinical Lung Cancer23 citations Open access
Semantic Scholar
TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
F. Meric-Bernstam, A. Spira, A. Lisberg, J. Sands +14 more
202122 citations
Semantic Scholar
Small Cell Lung Cancer, Version 2.2022
A. Ganti, B. Loo, M. Bassetti, C. Blakely +30 more
202120 citations
Semantic Scholar
Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).
A. Lisberg, J. Sands, Toshio Shimizu, J. Greenberg +11 more
202017 citations
Semantic Scholar
Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy.
I. Yambayev, T. Sullivan, K. Rieger-Christ, Elliot L. Servais +5 more
2022Lung Cancer14 citations
Semantic Scholar
Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors
L. Raez, Kathleen Danenberg, D. Sumarriva, J. Usher +8 more
2021Cancer Drug Resistance12 citations Open access
Semantic Scholar
A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).
K. Yoh, Y. Goto, Michael Thomas, A. Spira +11 more
202112 citations
Semantic Scholar
First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
J. Sands, Toshio Shimizu, E. Garon, J. Greenberg +9 more
2018Journal of Clinical Oncology12 citations
Semantic Scholar
Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients
Ernest N. Lo, L. Beckett, C. Pan, D. Robles +3 more
2015Prostate Cancer and Prostatic Disease12 citations Open access
Semantic Scholar
P47.05 A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)
M. Johnson, A. Spira, K. Yoh, R. Heist +7 more
2021Journal of Thoracic Oncology8 citations Open access
Semantic Scholar
The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.
P. Shah, J. Sands, N. Normanno
2021Lung Cancer8 citations Open access
Semantic Scholar
Neurologic complications of lung cancer
J. Sands, M. Daly, E. Lee
2020Cancer8 citations Open access
Semantic Scholar
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
J. Sands, M. Reck, A. Navarro, A. Chiang +10 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
Pathologic and Gene Expression Comparison of CT- Screen Detected and Routinely Detected Stage I/0 Lung Adenocarcinoma in NCCN Risk-Matched Cohorts.
Eric J. Burks, Jia-Rui Zhang, T. Sullivan, Xingyi Shi +11 more
2021Cancer Treatment and Research Communications7 citations Open access
Semantic Scholar
O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*
Toshio Shimizu, A. Lisberg, J. Sands, J. Greenberg +12 more
2021Annals of Oncology6 citations Open access
Semantic Scholar
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
W. Talcott, J. Miccio, Henry S. Park, A. White +8 more
2021Lung Cancer5 citations
Semantic Scholar
Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue
Parth S. Shah, S. Murarka, A. Joshi, Bhavna Mehta +4 more
2018Breast Cancer5 citations Open access
Semantic Scholar
Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.
T. Semrad, Edward J. Kim, Michael S. Tanaka, J. Sands +9 more
20165 citations
Semantic Scholar
Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article B Cell Reductive Therapy with Rituximab in the Treatment of Rheumatoid Arthritis
J. Tuscano, J. Sands
5 citations
Semantic Scholar
Outcomes of Positive and Suspicious Findings in Clinical Computed Tomography Lung Cancer Screening and the Road Ahead
S. Regis, Andrea Borondy-Kitts, A. McKee, K. Rieger-Christ +3 more
2021Annals of the American Thoracic Society4 citations Open access
Semantic Scholar
Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).
A. Qin, G. Kalemkerian, J. Patel, N. Mohindra +13 more
2021Journal of Clinical Oncology4 citations
Semantic Scholar
S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).
A. Argiris, Jie-Ling Miao, M. Cristea, Allen M. Chen +14 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
Clinical Utility of Next-Generation Sequencing in Tumors Diagnosed as Lung Squamous Cell Carcinoma: Real-World Data of Diagnostic and Therapeutic Implications.
I. Odintsov, Stephanie E. Siegmund, Federica Pecci, B. Ricciuti +5 more
2026Modern Pathology2 citations
Semantic Scholar
Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer
B. Ricciuti, A. Naqash, J. Naidoo, Kartik Sehgal +19 more
2020JTO Clinical and Research Reports2 citations Open access
Semantic Scholar
Consensus on Molecular Testing in Lung Cancer
P. Shah, J. Sands
2018Current Pulmonology Reports2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Heist×9
Invite
R. Heist — researcher profile on SciRah
A. Spira×9
Invite
A. Spira — researcher profile on SciRah
J. Greenberg×9
Invite
J. Greenberg — researcher profile on SciRah
M. Johnson×8
Invite
M. Johnson — researcher profile on SciRah

×8

Invite

K. Yoh — researcher profile on SciRah

Invite

K. Kelly — researcher profile on SciRah

Invite

G. Oxnard — researcher profile on SciRah

Invite

F. Guevara — researcher profile on SciRah

Invite

E. Garon — researcher profile on SciRah

F. Kobayashi×6

Invite

F. Kobayashi — researcher profile on SciRah

F. Meric-Bernstam×6

Invite

F. Meric-Bernstam — researcher profile on SciRah

Toshio Shimizu×6

Invite

Toshio Shimizu — researcher profile on SciRah